WordNet

a nonsteroidal anti-inflammatory drug (trade name Relafen) (同)Relafen

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/01/22 11:28:11」(JST)

wiki en

Nabumetone is a non-steroidal anti-inflammatory drug^[1] (NSAID), the only 1-naphthaleneacetic acid derivative. Nabumetone has been developed by Beecham. It is available under numerous brand names, such as Relafen, Relifex, and Gambaran.

Introduction

Nabumetone is a non acidic NSAID that is rapidly metabolized in the liver to a major active metabolite, 6-methoxy-2-naphthyl acetic acid. As found with previous NSAIDs, nabumetone's active metabolite inhibits the cyclooxygenase enzyme and preferentially blocks COX-2 activity (which is indirectly responsible for the production of inflammation and pain during arthritis). The active metabolite of nabumetone is felt to be the compound primarily responsible for therapeutic effect. Comparatively, the parent drug is a poor inhibitor of COX-2 byproducts, particularly prostaglandins. It may be less nephrotoxic than indomethacin.^[2]

Nabumetone belongs to a new class of NSAID with a lower potential for causing gastrointestinal mucosal irritancy and inhibition of platelet function,^[3] little effect on renal prostaglandin secretion and less of an association with heart failure than other traditional drugs of the class.^[4] Effects of nabumetone on blood pressure control in hypertensive patients on ACE inhibitors is also good—equivalent to Paracetamol.^[5]

Uses

It is used to treat pain or inflammation caused by arthritis or other inflammatory diseases and conditions like synovitis. Nabumetone works by reducing the effects of enzymes that cause pain and inflammation.^{[citation needed]}

Side effects

It has been shown to have a slightly lower risk of gastrointestinal side effects than most other non-selective NSAIDs since it is a non-acidic prodrug which is then metabolized to its active 6MNA (6-methoxy-2-naphthylacetic acid) form.^{[citation needed]}

Assay of nabumetone

There are few papers published reporting analytical methods^[6] for nabumetone.^[7] Two of them employed HPLC with UV-detection.^[8]^[9] One HPLC method using direct injection on restricted access media columns.^[10] Flow injection analysis (FIA) with UV-detection was also reported for the determination of nabumetone in pharmaceutical preparations.^[11] Methods using HPLC with fluorescence detection ^[12]^[13]^[14]^[15] were reported. M. Nobilis et al. carried out biotransformation and disposition studies in humans and minipigs using HPLC with UV, fluorescence and mass spectrometric detection. The interactions with gamma-cyclodextrin were also studied by fluorescence measurements. Assay methods employed HPLC using UV detection,^[7] photodiode array (PDA) detector^[16]^[17] and mass spectrometric detection for the determination of nabumetone and its metabolites. Murillo Pulgarín et al.^[18]^[19]^[20] reported three analytical methods using different techniques along with phosphorescence. Liquid chromatography methods using different techniques of mass spectrometry were also reported.^[21]^[22]^[23] The electrochemical behavior of nabumetone by a voltammetric technique ^[24] and a novel colorimetric method based on chemical derivatization ^[25] were also published. P. K. Sahu et al.^[26] has reported a HPLC method for simultaneous estimation of Nabumetone and Paracetamol in combined dosage form.

References

^ Gonzalo-Garijo MA, Cordobés-Duran C, Lamilla-Yerga AM, Moreno-Gastón I (2007). "Severe immediate reaction to nabumetone". Journal of Investigational Allergology and Clinical Immunology : official organ of the International Association of Asthmology (INTERASMA) and Sociedad Latinoamericana de Alergia e Inmunología 17 (4): 274–6. PMID 17694703.
^ Olsen, N V; Jensen, N G; Hansen, J M; Christensen, N J; Fogh-Andersen, N; Kanstrup, I L (1999). "Non-steroidal anti-inflammatory drugs and renal response to exercise: a comparison of indomethacin and nabumetone". Clin Sci. 97: 457–465. doi:10.1042/cs0970457.
^ Jorgen, Kristensen; Andreas, Viklund; Nils, Feltelius; Anders, Larsson (1996). "Effects of nabumetone on platelet function in healthy volunteers". Platelets 7: 149–152. doi:10.3109/09537109609023573.
^ Donnan, P T (2000). "098. A Drug-Safety Study to Examine the Possible Association of Congestive Heart Failure with Dispensed Nabumetone, Ibuprofen and other Non-Steroidal Anti-inflammatory Drugs". Pharmacoepidemiol Drug Safety 8 (S2): S115. doi:10.1002/(SICI)1099-1557(199908)8:2+<S79::AID-PDS429>3.0.CO;2-2. line feed character in |title= at position 49 (help)
^ Palmer Robert, H; Haig Ann, E; Flavin Susan, K; Iyengar Malini, K (2001). Am J Hypertens 14 (S1): 85A. Missing or empty |title= (help)
^ Małgorzata, Starek; Jan, Krzek (2009). "A review of analytical techniques for determination of oxicams, nimesulide and nabumetone". Talanta 77: 925–942. doi:10.1016/j.talanta.2008.09.022.
^ ^a ^b Sahu, Prafulla Kumar; Annapurna, M. Mathrusri (2009). "Analysis of Nabumetone in Bulk and Tablet Formulation by a New and Validated Reverse Phase High Performance Liquid Chromatography". E-Journal of Chemistry. 6(S1): S59–S64. ISSN 0973-4945.
^ Al-Momani Idrees, F. "Determination of Nabumetone and Its Major Metabolite in Plasma and Tablet Formulations by Reverse-Phase HPLC". Anal Lett. 1997 (30): 2485–2492. doi:10.1080/00032719708001759.
^ Jang, E J; Lee, Y J; Park, M G; Shim, C K (1995). "HPLC Assay of 6-Methoxy-2-Naphthylacetic Acid, a Major Metabolite of Nabumetone, in Human Serum". Anal Lett. 28: 2379–2389. doi:10.1080/00032719508000379.
^ Ahsanul, Haque; Stewart James, T (1999). "Direct injection hplc analysis of some non‐steroidal anti‐inflammatory drugs on restricted access media columns". Biomed Chromatogr 13: 51–56. doi:10.1002/(sici)1099-0801(199902)13:1<51::aid-bmc814>3.3.co;2-k.
^ Can, N O; Tuncel, M; Aboul-Enein, H Y (2003). "Determination of nabumetone in pharmaceutical formulation by flow injection analysis (FIA) with UV-detection.". Pharmazie 58: 22–24. PMID 12622247.
^ Mikami, E; Goto, T; Ohno, T; Matsumoto, H; Nishida, M (2000). "Simultaneous analysis of naproxen, nabumetone and its major metabolite 6-methoxy-2-naphthylacetic acid in pharmaceuticals and human urine by high-performance liquid chromatography". J Pharm Biomed Anal. 23: 917–925. doi:10.1016/s0731-7085(00)00365-4.
^ Kobylińska, Kamila; Barlińska, Małgorzata; Kobylińska, Maria. "Analysis of nabumetone in human plasma by HPLC. Application to single dose pharmacokinetic studies". J Pharm Biomed Anal. 2003 (32): 323–328. doi:10.1016/S0731-7085(03)00078-5.
^ Nobilis, M; Kopecký, J; Kv, Tina J; Svoboda, Z; Pour, M; Kune, J; Hol, Apek M; Kolá, Ová L (2003). "Comparative biotransformation and disposition studies of nabumetone in humans and minipigs using high-performance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection". J Pharm Biomed Anal. 32: 641–656. doi:10.1016/s0731-7085(03)00171-7.
^ Al-Rawashdeh, A F Nathir (2005). "Interactions of Nabumetone with γ-Cyclodextrin Studied by Fluorescence Measurements". J Inclusion Phenomena and Macrocyclic Chem. 51 (1-2): 27–32. doi:10.1007/s10847-004-1502-9.
^ Nageswara, Rao R; Meena, S; Nagaraju, D; Raghu Ram, Rao A (2004). "Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological ﬂuids". Biomed Chromatogr 19: 362–368. doi:10.1002/bmc.458.
^ Nobilis, M; Holcapek, M; Kolárová, L; Kopecký, J; Kunes, M; Svoboda, Z; Kvetina, J (2004). "Identification and determination of phase II nabumetone metabolites by high-performance liquid chromatography with photodiode array and mass spectrometric detection". J Chromatogr. A 1031: 229–236. doi:10.1016/j.chroma.2004.01.031.
^ Murillo, Pulgarín J A; Alañón, Molina A; Alañón, Pardo M T (2005). "Simplex optimization and kinetic determination of nabumetone in pharmaceutical preparations by micellar—stabilized room temperature phosphorescence". Analytica Chimica Acta 528: 77–82. doi:10.1016/j.aca.2004.10.014.
^ Murillo, Pulgarín J A; Alañón, Molina A; Alañón, Pardo M T (2005). "Simplex optimization of the variables affecting the micelle-stabilized room temperature phosphorescence of 6-methoxy-2-naphthylacetic acid and its kinetic determination in human urine". Anal Biochem 339: 157–164. doi:10.1016/j.ab.2005.01.012.
^ Pulgarín; Murillo, Jose A; Aurelia Alañón, Molina; Robles Ignacio, Sánchez-Ferrer (2005). "Simple and rapid determination of the active metabolite of nabumetone in biological fluids by heavy atom-induced room temperature phosphorescence". Analytica Chimica Acta. 554: 37–42. doi:10.1016/j.aca.2005.08.040.
^ Patel Bhavin, N; Naveen, Sharma; Mallika, Sanyal; Arpana, Prasad; Shrivastav Pranav, S (2008). "High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study". Biomed Chromatogr 22: 1213–1224. doi:10.1002/bmc.1047.
^ Wolff, J C; Hawtin, P N; Monté, S; Balogh, M; Jones, T (2001). "The use of particle beam mass spectrometry for the measurement of impurities in a nabumetone drug substance, not easily amenable to atmospheric pressure ionisation techniques". Rapid Commun Mass Spectrom 15: 265–272. doi:10.1002/rcm.214.
^ Sheen, J F; Her, G R (December 2004). "Application of pentafluorophenyl hydrazine derivatives to the analysis of nabumetone and testosterone in human plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry". Anal Bioanal Chem 380 (7–8): 891–7. doi:10.1007/s00216-004-2877-6.
^ Yuksel, Altun; Burcu, Dogan; Ozkan Sibel, A; Bengi, Uslu (2007). "Development and Validation of Voltammetric Techniques for Nabumetone in Pharmaceutical Dosage Form, Human Serum and Urine". Acta Chim Slov. 54: 287–294.
^ Adegoke, A O; Idowu, S O; Olaniyi, A A (2007). "Novel determination of nabumetone, a cox-2 inhibitor precursor via its 4-carboxyl-2,6-dinitrobenzene diazonium (CDNBD) derived AZO dye.". Afr J Med Med Sci. 36: 249–257. PMID 18390065.
^ Sahu, Prafulla Kumar; Annapurna, M. Mathrusri; Sahoo, Dillip Kumar (2011). "A Simple and Sensitive HPLC Method for Simultaneous Analysis of Nabumetone and Paracetamol in Pharmaceutical Formulations" (PDF). E-Journal of Chemistry 8 (S1): S41–S46. doi:10.1155/2011/607069.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. COX-2選択的阻害剤の概要 overview of selective cox 2 inhibitors
2. 非ステロイド性抗炎症剤（NSAIDs）：作用機序 nsaids mechanism of action
3. 非選択性非ステロイド性抗炎症剤（NSAIDs）：心血管系への有害作用 nonselective nsaids adverse cardiovascular effects
4. 最後の数週間における疼痛の評価およびマネージメント pain assessment and management in the last weeks of life
5. 癌疼痛のマネージメント：アセトアミノフェンおよび非ステロイド性抗炎症剤の使用 cancer pain management use of acetaminophen and nonsteroidal antiinflammatory drugs

English Journal

Synthesis and antidiabetic performance of β-amino ketone containing nabumetone moiety.

Wang H, Yan JF, Song XL, Fan L, Xu J, Zhou GM, Jiang L, Yang DC.SourceSchool of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, China.
Bioorganic & medicinal chemistry.Bioorg Med Chem.2012 Mar 15;20(6):2119-30. Epub 2012 Feb 2.
We wish to report the further design and improved synthesis that resulted in two series of target molecules, TM-1 and TM-2, with remarkably simplified structures containing β-amino ketone of discrete nabumetone moiety. These were obtained via a 'one-pot, two-step, three-component' protocol of Manni
PMID 22364952

Toxicology of frequently encountered nonsteroidal anti-inflammatory drugs in dogs and cats.

Khan SA, McLean MK.SourceASPCA Animal Poison Control Center, 1717 South Philo Road, Suite 36, Urbana, IL 61802, USA. safdar.khan@aspca.org
The Veterinary clinics of North America. Small animal practice.Vet Clin North Am Small Anim Pract.2012 Mar;42(2):289-306, vi-vii.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a group of heterogeneous compounds extensively used in both human and veterinary medicine for their antipyretic, anti-inflammation, and analgesic properties. NSAIDs consist of a wide range of pharmacologically active agents with different chemical st
PMID 22381180

Japanese Journal

In Vitro Characterization of the Cytochrome P450 Isoforms Involved in the Metabolism of 6-Methoxy-2-napthylacetic Acid, an Active Metabolite of the Prodrug Nabumetone

Matsumoto Kaori,Nemoto Eiichi,Hasegawa Tetsuya,Akimoto Masayuki,Sugibayashi Kenji
Biological & Pharmaceutical Bulletin 34(5), 734-739, 2011
… The cytochrome P450 (CYP) isoforms that catalyze the oxidation metabolism of 6-methoxy-2-napthylacetic acid (6-MNA), an active metabolite of nabumetone, were studied in rats and humans. …
NAID 130000657788

アルブミンサイト2結合阻害薬である6-メトキシー2-ナフチル酢酸によるフチルビプロフェンの蛋白結合阻害に関する基礎的検討

徳永仁,高村徳人,緒方賢次,吉田裕樹,瀬戸口奈央,近藤照義,西尾豊隆,川井恵一
九州保健福祉大学研究紀要 11, 153-158, 2010-03
非ステロイド性抗炎症薬(NSAID)フルルビプロフェン(FP)の蛋白結合率は約99%であり、組織移行性が低い。6-メトキシ-2-ナフチル酢酸(6MNA)は、NSAIDの1つであるナブメトンの活性代謝産物である。これらの薬物は、ともにヒト血清アルブミン(HSA)のサイトIIに強く結合する。私たちは、LLC-PK1を用いて6MNA添加時のFPの細胞膜透過性について調べた。この実験では、細胞膜プレートの …
NAID 110007577972

Related Pictures

★リンクテーブル★

リンク元

「ナブメトン」

Nabumetone
Systematic (IUPAC) name
	4-(6-methoxy-2-naphthyl)-2-butanone
Clinical data
AHFS/Drugs.com	monograph
MedlinePlus	a692022
Legal status	AU: S4 (Prescription only); POM;
Routes of; administration	Oral
Pharmacokinetic data
Protein binding	> 99% (active metabolite)
Metabolism	Hepatic, to active metabolite 6-methoxy-2-naphthylacetic acid; 6-MNA
Biological half-life	23 hours (active metabolite)
Excretion	Renal
Identifiers
CAS Number	42924-53-8
ATC code	M01AX01
PubChem	CID: 4409
IUPHAR/BPS	7245
DrugBank	DB00461
ChemSpider	4256
UNII	LW0TIW155Z
KEGG	D00425
ChEBI	CHEBI:7443
ChEMBL	CHEMBL1070
Chemical data
Formula	C15H16O2
Molecular mass	228.29 g/mol
	SMILES O=C(C)CCc1ccc2c(c1)ccc(OC)c2 ;
	InChI InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3 ; Key:BLXXJMDCKKHMKV-UHFFFAOYSA-N ;
(what is this?) (verify)

　　[★]

英: nabumetone
商: レリフェン
関: 非ステロイド性抗炎症薬

-nabumetone

[pmid17694703-1] Gonzalo-Garijo MA, Cordobés-Duran C, Lamilla-Yerga AM, Moreno-Gastón I (2007). "Severe immediate reaction to nabumetone". Journal of Investigational Allergology and Clinical Immunology : official organ of the International Association of Asthmology (INTERASMA) and Sociedad Latinoamericana de Alergia e Inmunología 17 (4): 274–6. PMID 17694703.

[2] Olsen, N V; Jensen, N G; Hansen, J M; Christensen, N J; Fogh-Andersen, N; Kanstrup, I L (1999). "Non-steroidal anti-inflammatory drugs and renal response to exercise: a comparison of indomethacin and nabumetone". Clin Sci. 97: 457–465. doi:10.1042/cs0970457.

[3] Jorgen, Kristensen; Andreas, Viklund; Nils, Feltelius; Anders, Larsson (1996). "Effects of nabumetone on platelet function in healthy volunteers". Platelets 7: 149–152. doi:10.3109/09537109609023573.

[4] Donnan, P T (2000). "098. A Drug-Safety Study to Examine the Possible Association of Congestive Heart Failure with Dispensed Nabumetone, Ibuprofen and other Non-Steroidal Anti-inflammatory Drugs". Pharmacoepidemiol Drug Safety 8 (S2): S115. doi:10.1002/(SICI)1099-1557(199908)8:2+<S79::AID-PDS429>3.0.CO;2-2. line feed character in |title= at position 49 (help)

[5] Palmer Robert, H; Haig Ann, E; Flavin Susan, K; Iyengar Malini, K (2001). Am J Hypertens 14 (S1): 85A. Missing or empty |title= (help)

[6] Małgorzata, Starek; Jan, Krzek (2009). "A review of analytical techniques for determination of oxicams, nimesulide and nabumetone". Talanta 77: 925–942. doi:10.1016/j.talanta.2008.09.022.

[liquid-7] Sahu, Prafulla Kumar; Annapurna, M. Mathrusri (2009). "Analysis of Nabumetone in Bulk and Tablet Formulation by a New and Validated Reverse Phase High Performance Liquid Chromatography". E-Journal of Chemistry. 6(S1): S59–S64. ISSN 0973-4945.

[8] Al-Momani Idrees, F. "Determination of Nabumetone and Its Major Metabolite in Plasma and Tablet Formulations by Reverse-Phase HPLC". Anal Lett. 1997 (30): 2485–2492. doi:10.1080/00032719708001759.

[9] Jang, E J; Lee, Y J; Park, M G; Shim, C K (1995). "HPLC Assay of 6-Methoxy-2-Naphthylacetic Acid, a Major Metabolite of Nabumetone, in Human Serum". Anal Lett. 28: 2379–2389. doi:10.1080/00032719508000379.

[10] Ahsanul, Haque; Stewart James, T (1999). "Direct injection hplc analysis of some non‐steroidal anti‐inflammatory drugs on restricted access media columns". Biomed Chromatogr 13: 51–56. doi:10.1002/(sici)1099-0801(199902)13:1<51::aid-bmc814>3.3.co;2-k.

[11] Can, N O; Tuncel, M; Aboul-Enein, H Y (2003). "Determination of nabumetone in pharmaceutical formulation by flow injection analysis (FIA) with UV-detection.". Pharmazie 58: 22–24. PMID 12622247.

[12] Mikami, E; Goto, T; Ohno, T; Matsumoto, H; Nishida, M (2000). "Simultaneous analysis of naproxen, nabumetone and its major metabolite 6-methoxy-2-naphthylacetic acid in pharmaceuticals and human urine by high-performance liquid chromatography". J Pharm Biomed Anal. 23: 917–925. doi:10.1016/s0731-7085(00)00365-4.

[13] Kobylińska, Kamila; Barlińska, Małgorzata; Kobylińska, Maria. "Analysis of nabumetone in human plasma by HPLC. Application to single dose pharmacokinetic studies". J Pharm Biomed Anal. 2003 (32): 323–328. doi:10.1016/S0731-7085(03)00078-5.

[14] Nobilis, M; Kopecký, J; Kv, Tina J; Svoboda, Z; Pour, M; Kune, J; Hol, Apek M; Kolá, Ová L (2003). "Comparative biotransformation and disposition studies of nabumetone in humans and minipigs using high-performance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection". J Pharm Biomed Anal. 32: 641–656. doi:10.1016/s0731-7085(03)00171-7.

[15] Al-Rawashdeh, A F Nathir (2005). "Interactions of Nabumetone with γ-Cyclodextrin Studied by Fluorescence Measurements". J Inclusion Phenomena and Macrocyclic Chem. 51 (1-2): 27–32. doi:10.1007/s10847-004-1502-9.

[16] Nageswara, Rao R; Meena, S; Nagaraju, D; Raghu Ram, Rao A (2004). "Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological ﬂuids". Biomed Chromatogr 19: 362–368. doi:10.1002/bmc.458.

[17] Nobilis, M; Holcapek, M; Kolárová, L; Kopecký, J; Kunes, M; Svoboda, Z; Kvetina, J (2004). "Identification and determination of phase II nabumetone metabolites by high-performance liquid chromatography with photodiode array and mass spectrometric detection". J Chromatogr. A 1031: 229–236. doi:10.1016/j.chroma.2004.01.031.

[18] Murillo, Pulgarín J A; Alañón, Molina A; Alañón, Pardo M T (2005). "Simplex optimization and kinetic determination of nabumetone in pharmaceutical preparations by micellar—stabilized room temperature phosphorescence". Analytica Chimica Acta 528: 77–82. doi:10.1016/j.aca.2004.10.014.

[19] Murillo, Pulgarín J A; Alañón, Molina A; Alañón, Pardo M T (2005). "Simplex optimization of the variables affecting the micelle-stabilized room temperature phosphorescence of 6-methoxy-2-naphthylacetic acid and its kinetic determination in human urine". Anal Biochem 339: 157–164. doi:10.1016/j.ab.2005.01.012.

[20] Pulgarín; Murillo, Jose A; Aurelia Alañón, Molina; Robles Ignacio, Sánchez-Ferrer (2005). "Simple and rapid determination of the active metabolite of nabumetone in biological fluids by heavy atom-induced room temperature phosphorescence". Analytica Chimica Acta. 554: 37–42. doi:10.1016/j.aca.2005.08.040.

[21] Patel Bhavin, N; Naveen, Sharma; Mallika, Sanyal; Arpana, Prasad; Shrivastav Pranav, S (2008). "High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study". Biomed Chromatogr 22: 1213–1224. doi:10.1002/bmc.1047.

[22] Wolff, J C; Hawtin, P N; Monté, S; Balogh, M; Jones, T (2001). "The use of particle beam mass spectrometry for the measurement of impurities in a nabumetone drug substance, not easily amenable to atmospheric pressure ionisation techniques". Rapid Commun Mass Spectrom 15: 265–272. doi:10.1002/rcm.214.

[23] Sheen, J F; Her, G R (December 2004). "Application of pentafluorophenyl hydrazine derivatives to the analysis of nabumetone and testosterone in human plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry". Anal Bioanal Chem 380 (7–8): 891–7. doi:10.1007/s00216-004-2877-6.

[24] Yuksel, Altun; Burcu, Dogan; Ozkan Sibel, A; Bengi, Uslu (2007). "Development and Validation of Voltammetric Techniques for Nabumetone in Pharmaceutical Dosage Form, Human Serum and Urine". Acta Chim Slov. 54: 287–294.

[25] Adegoke, A O; Idowu, S O; Olaniyi, A A (2007). "Novel determination of nabumetone, a cox-2 inhibitor precursor via its 4-carboxyl-2,6-dinitrobenzene diazonium (CDNBD) derived AZO dye.". Afr J Med Med Sci. 36: 249–257. PMID 18390065.

[26] Sahu, Prafulla Kumar; Annapurna, M. Mathrusri; Sahoo, Dillip Kumar (2011). "A Simple and Sensitive HPLC Method for Simultaneous Analysis of Nabumetone and Paracetamol in Pharmaceutical Formulations" (PDF). E-Journal of Chemistry 8 (S1): S41–S46. doi:10.1155/2011/607069.

匿名

検索

案内

案内

nabumetone